Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance

Author:

Tait Jessica R.1,Harper Marina2ORCID,Cortés-Lara Sara34,Rogers Kate E.1,López-Causapé Carla34,Smallman Thomas R.2,Lang Yinzhi5,Lee Wee Leng1,Zhou Jieqiang5,Bulitta Jürgen B.5ORCID,Nation Roger L.1,Boyce John D.2ORCID,Oliver Antonio34ORCID,Landersdorfer Cornelia B.1ORCID

Affiliation:

1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

2. Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Victoria, Australia

3. Servicio de Microbiología, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain

4. CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain

5. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA

Abstract

Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug-resistant hypermutable P. aeruginosa isolates in the hollow-fiber infection model (HFIM). Isolates CW41, CW35, and CW44 (ceftolozane-tazobactam MICs of 4, 4, and 2 mg/L, respectively) from adults with CF were exposed to simulated representative epithelial lining fluid pharmacokinetics of ceftolozane-tazobactam in the HFIM.

Funder

DHAC | National Health and Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference73 articles.

1. Cystic Fibrosis Foundation. 2022. Cystic fibrosis foundation patient registry 2021 annual data report. https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf. Accessed 26 March 2023.

2. Predictors of mortality in adults with cystic fibrosis

3. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis

4. High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection

5. Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3